Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MC4R | P32245 | 6/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | FABP3 | P05413 | 1/20 | 0.39 |
| ▸ | FABP4 | P15090 | 1/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | PRKCA | P17252 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.38 |
| ▸ | SETDB1 | Q15047 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6503772 | 0.79 | CKS1B (0.48) | KMT2AF10PIM2 | |
| SCHEMBL6221717 | 0.75 | F10 (0.48) | MEN1KMT2AGAAMC4RF10 | |
| SCHEMBL5073799 | 0.74 | MEN1 (0.41) | MEN1KMT2AGAAMC4RKDM4E | |
| SCHEMBL2558725 | 0.72 | FABP3 (0.59) | MEN1KMT2AGAAKDM4EALDH1A1 | |
| SCHEMBL5073795 | 0.72 | MEN1 (0.42) | MEN1KMT2AGAAMC4RKDM4E | |
| SCHEMBL16814966 | 0.71 | GAA (0.51) | MEN1KMT2AGAAKDM4EALDH1A1 | |
| SCHEMBL6492610 | 0.71 | KMT2A (0.37) | MEN1KMT2AGAAMC4RUSP2 | |
| SCHEMBL27701838 | 0.69 | NPC1 (0.45) | MEN1KMT2AGAAKDM4EALDH1A1 | |
| SCHEMBL8006206 | 0.69 | CKS1B (0.52) | KMT2AGAA | |
| SCHEMBL7465114 | 0.68 | NPC1 (0.51) | MEN1KMT2AGAAMAPTUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212054-A1 | Substituted amino methyl factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-13 | — | — | US | claimed |
| US-6949550-B2 | Substituted amino methyl factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-09-27 | — | — | US | disclosed |
| US-20030212054-A1 | Substituted amino methyl factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212054-A1 | Substituted amino methyl factor Xa inhibitors | F11, F10, F9 | MEN1 1315/4885KMT2A 179/4885GAA 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.